Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii.

The Journal of antibiotics - 1 Jan 2010

Cui Jun-Chang, Liu You-Ning, Chen Liang-An

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acinetobacter baumannii
Share to Acinetobacter Infections
Share to Anti-Bacterial Agents
Share to Carbapenems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Bacterial

Share to Microbial Sensitivity Tests

Share to Minocycline

Share to Tigecycline

Source

Identifiers

PMID: 19911030
DOI: 10.1038/ja.2009.111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii.PMID 19911030Read ↗

Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus.Semantic proximity Read ↗

Mutant prevention concentrations of imipenem and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii.Semantic proximity Read ↗

Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.Semantic proximity Read ↗

New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.Semantic proximity Read ↗

Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii.Semantic proximity Read ↗

Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.Semantic proximity Read ↗

The mutant selection window and antimicrobial resistance.Semantic proximity Read ↗

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Semantic proximity Read ↗

Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolatesSemantic proximity Read ↗

In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.Semantic proximity Read ↗

Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.Semantic proximity Read ↗

Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.